Compounds for the treatment of hiv infection and other diseases caused by rna viruses
AssigneeUniversidad CatóLica De Valencia “San Vicente MáRtir”
InventorsJose GALLEGO SALA, Silvia PRADO MARTIN, Jose ALCAMI PERTEJO
Life of this patent
Estimating the term…
Abstract
Use of organic compounds for the treatment of the infection caused by human immunodeficiency virus type 1 (HIV-1), as well as other diseases caused by RNA viruses is disclosed.
Claims40
A method for the treatment of infections caused by RNA viruses, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I):
- or a salt or solvate thereof, wherein
- R1 and R2 are independently selected from H, halogen, OR′, OC(O)R′, C(O)R′, C(O)OR′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
- or
- R1 and R2 form, together with the carbon atom to which they are attached, a 5-membered carbocycle or heterocycle;
- each R3 and R4 is independently selected from halogen, OC(O)R′, SOR′, SO2R′, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, and a group of formula (A), wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
- or two contiguous R3 or R4 groups form a benzene ring;
- R5 is selected from H, halogen, OC(O)R′, SOR′, SO2R′, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, and a group of formula (A), wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
- R6 is selected from H, halogen, OC(O)R′, SOR′, SO2R′, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, and a group of formula (A), wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
- n represents 0, 1, 2, 3, or 4;
- and
- m represents 0, 1, 2, 3, or 4;
- wherein at least one of R3, R4, R5, and R6 is a group of formula (A)
- wherein
- Z is selected from 5- to 10-membered heterocyclyl, 0, 5, and NR′, wherein R′ represents H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, or 5- to 10-membered heterocyclyl;
- each Ra and Rb is independently selected from H, halogen, OR′, OC(O)R′, NR′2, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C2-6)alkyl, and 5- to 10-membered heterocyclyl;
- Y is selected from H, OR′, OC(O)R′, NR′2, +NR′3, C(O)R′, C(O)OR′, OC(O)NR′2, C(O)NR′2, SR′, SOR′, SO2R′, C3-7 cycloalkyl, C6-12 aryl, and 5- to 10-membered heterocyclyl, wherein each R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
- p represents 0, 1, 2, 3, 4, 5, or 6;
- and
- q represents 0, 1, 2, or 3.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for the treatment of infections caused by RNA viruses, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (II):
- or a salt or a solvate thereof, wherein
- R1, R2, and R4 are independently selected from H, halogen, OR′, OC(O)R′, SR′, SOR′, SO2R′, NR′2, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
- X is selected from O, S, SO, and SO2;
- R3 is selected from C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted;
- and
- R5 and R6 are independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, 5- to 10-membered heterocyclyl, or R5 and R6 form, together with the nitrogen atom to which they are attached, an optionally substituted 5- to 10-membered heterocyclyl.
(canceled)
(canceled)
A method for the treatment of infections caused by RNA viruses, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (III):
- or a salt or a solvate thereof, wherein
- R2, R3, R4, R5, R6, and R7 are independently selected from H, halogen, OR′, OC(O)R′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, 5- to 7-membered heterocyclyl, optionally substituted, SR′, SOR′, SO2R′, NR′2, C(O)R′, C(O)OR′, CN, and NO2, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 7-membered heterocyclyl, optionally substituted;
- R1 is selected from NR′, O, S, H, halogen, OR′, OC(O)R′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, 5- to 7-membered heterocyclyl, optionally substituted, SR′, SOR′, SO2R′, NR′2, C(O)R′, C(O)OR′, CN, and NO2, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 7-membered heterocyclyl, optionally substituted;
- R8 can be absent or selected from C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 7-membered heterocyclyl, optionally substituted;
- and
- represents a single bond or a double bond, such that one of the two bonds indicated as (NC or CR1) represents a single bond and the other a double bond.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.